OTTAWA (dpa-AFX) - Endo International plc (ENDP) has decided to withdraw its
supplemental New Drug Application relating to specific abuse deterrent labeling
for OPANA ER.
OPANA ER is an opioid agonist indicated for the management of pain severe...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.